Bavencio 200 mg/10 ml, concentrate for solution for infusion

( ARTG ) BAVENCIO is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC). This indication is approved based on tumour response rate, duration of response in a single arm study.,BAVENCIO is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.,BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).